Horien Biochemical Technology (7814) reported revenue of NT$4.7 million for Oct 2026, -7.4% year on year and -44.2% from the previous month. Revenue for Jan–Oct 2026 was NT$82.3 million (+35.8% year on year).
In Oct 2026, it ranked No. 139 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$4.7 million | -7.4% | -44.2% |
| Sep 2026 | NT$8.5 million | +4.0% | +19.1% |
| Aug 2026 | NT$7.1 million | +12.7% | -47.8% |
| Jul 2026 | NT$13.7 million | +36.5% | -7.2% |
| Jun 2026 | NT$14.8 million | +209.3% | +229.2% |
| May 2026 | NT$4.5 million | -29.8% | -16.3% |
| Apr 2026 | NT$5.4 million | +3.3% | -66.5% |
| Mar 2026 | NT$16 million | +112.1% | +452.8% |
| Feb 2026 | NT$2.9 million | -13.6% | -39.5% |
| Jan 2026 | NT$4.8 million | +27.2% | -61.2% |
| Dec 2025 | NT$12.3 million | -25.3% | +22.5% |
| Nov 2025 | NT$10.1 million | +16.1% | +96.5% |
| Oct 2025 | NT$5.1 million | +1.4% | -37.4% |
| Sep 2025 | NT$8.2 million | -41.1% | +29.0% |
| Aug 2025 | NT$6.3 million | +0.7% | -36.7% |
| Jul 2025 | NT$10 million | -14.7% | +110.2% |
| Jun 2025 | NT$4.8 million | +4.3% | -25.2% |
| May 2025 | NT$6.4 million | +13.7% | +23.1% |
| Apr 2025 | NT$5.2 million | +43.8% | -31.2% |
| Mar 2025 | NT$7.5 million | -43.4% | +125.2% |
| Feb 2025 | NT$3.3 million | -15.5% | -11.0% |
| Jan 2025 | NT$3.8 million | -22.2% | -77.2% |
| Dec 2024 | NT$16.5 million | +973.3% | +90.4% |
| Nov 2024 | NT$8.7 million | — | +71.6% |
| Oct 2024 | NT$5.1 million | — | -63.6% |
Jan–Oct 2026 cumulative: NT$82.3 million (+35.8% YoY)
Other Biotech & Medical companies
Compare with peers: Horien Biochemical Technology vs PEC / Horien Biochemical Technology vs Lotus Pharm / Horien Biochemical Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主係客戶需求增加所致
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16